Lifestyle, exercise and activity package for people living with progressive multiple sclerosis (LEAP-MS): protocol for a single-arm feasibility study.
Feasibility study
Intervention
Multiple sclerosis
Physical activity
Physiotherapy
Self-management
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
22 May 2021
22 May 2021
Historique:
received:
20
05
2020
accepted:
11
05
2021
entrez:
23
5
2021
pubmed:
24
5
2021
medline:
24
5
2021
Statut:
epublish
Résumé
We have co-designed a tailored blended physiotherapy intervention for people with progressive multiple sclerosis (PwPMS) who often struggle to access support for physical activity. Underpinned by self-management principles, the Lifestyle, Exercise and Activity Package for people with Multiple Sclerosis (LEAP-MS) intervention incorporates face-to-face or online physiotherapy coaching sessions with an accompanying online physical activity platform. The LEAP-MS platform is a multi-user system enabling user and physiotherapist to co-create activity plans. The LEAP-MS platform consists of an information and activity suite, interactive components enabling selection of exercises into an activity programme, goal setting and activity logging. The platform also facilitates online remote support from a physiotherapist through an embedded online messaging function. We aim to evaluate the LEAP-MS platform in a feasibility trial. LEAP-MS will be evaluated within a single-arm feasibility study with embedded process evaluation. After registration and initial eligible screening, 21 participants will be required to complete baseline self-completion measures. This will be followed by an initial home-based or online coaching session with a physiotherapist (who has received tailored self-management and digital resource training) and access to the online intervention for an initial 3-month period. During this period, participants are given the option to request up to five further home-based or online physiotherapy coaching sessions. Follow-up questionnaires and semi-structured interviews will be administered 3 months after baseline with participants and intervention physiotherapists. The LEAP-MS platform will be available to participants for a further 3 months. Usage of the LEAP-MS platform will be tracked during the full 6-month period and final follow-up will be conducted 6 months after baseline. Feasibility outcomes (recruitment, retention, intervention uptake and safety) will be reported. The process evaluation will be undertaken to identify possible mechanisms for any observed effects. The data will inform full-scale evaluations of this co-produced, blended physiotherapy intervention. ClinicalTrials.gov , NCT03951181 . Registered 15 May 2019.
Sections du résumé
BACKGROUND
BACKGROUND
We have co-designed a tailored blended physiotherapy intervention for people with progressive multiple sclerosis (PwPMS) who often struggle to access support for physical activity. Underpinned by self-management principles, the Lifestyle, Exercise and Activity Package for people with Multiple Sclerosis (LEAP-MS) intervention incorporates face-to-face or online physiotherapy coaching sessions with an accompanying online physical activity platform. The LEAP-MS platform is a multi-user system enabling user and physiotherapist to co-create activity plans. The LEAP-MS platform consists of an information and activity suite, interactive components enabling selection of exercises into an activity programme, goal setting and activity logging. The platform also facilitates online remote support from a physiotherapist through an embedded online messaging function. We aim to evaluate the LEAP-MS platform in a feasibility trial.
METHODS
METHODS
LEAP-MS will be evaluated within a single-arm feasibility study with embedded process evaluation. After registration and initial eligible screening, 21 participants will be required to complete baseline self-completion measures. This will be followed by an initial home-based or online coaching session with a physiotherapist (who has received tailored self-management and digital resource training) and access to the online intervention for an initial 3-month period. During this period, participants are given the option to request up to five further home-based or online physiotherapy coaching sessions. Follow-up questionnaires and semi-structured interviews will be administered 3 months after baseline with participants and intervention physiotherapists. The LEAP-MS platform will be available to participants for a further 3 months. Usage of the LEAP-MS platform will be tracked during the full 6-month period and final follow-up will be conducted 6 months after baseline.
DISCUSSION
CONCLUSIONS
Feasibility outcomes (recruitment, retention, intervention uptake and safety) will be reported. The process evaluation will be undertaken to identify possible mechanisms for any observed effects. The data will inform full-scale evaluations of this co-produced, blended physiotherapy intervention.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov , NCT03951181 . Registered 15 May 2019.
Identifiants
pubmed: 34022955
doi: 10.1186/s40814-021-00852-w
pii: 10.1186/s40814-021-00852-w
pmc: PMC8140324
doi:
Banques de données
ClinicalTrials.gov
['NCT03951181']
Types de publication
Journal Article
Langues
eng
Pagination
111Subventions
Organisme : Multiple Sclerosis Society
ID : 81
Pays : United Kingdom
Références
Disabil Rehabil. 2012;34(22):1887-93
pubmed: 22480377
Mult Scler. 2016 Aug;22(2 Suppl):34-46
pubmed: 27465614
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
Nat Rev Neurol. 2012 Sep;8(9):487-97
pubmed: 22825702
Brain. 2001 May;124(Pt 5):962-73
pubmed: 11335698
Clin Rehabil. 2011 Jul;25(7):588-98
pubmed: 21382866
Arch Phys Med Rehabil. 2016 Sep;97(9 Suppl):S210-7
pubmed: 27211007
Br J Gen Pract. 2005 May;55(514):378-83
pubmed: 15904557
BMJ Open. 2021 Mar 16;11(3):e045378
pubmed: 33727274
Ther Adv Neurol Disord. 2016 Jul;9(4):327-35
pubmed: 27366240
Br J Sports Med. 2009 Feb;43(2):99-101
pubmed: 18838405
JMIR Res Protoc. 2019 Mar 01;8(3):e12319
pubmed: 30821692
Contemp Clin Trials. 2018 Aug;71:154-161
pubmed: 29959105
BMJ Open. 2017 Feb 17;7(2):e013537
pubmed: 28213598
J Rehabil Med. 2012 Oct;44(10):811-23
pubmed: 22990349
J Man Manip Ther. 2009;17(3):163-70
pubmed: 20046623
Trials. 2021 Apr 16;22(1):286
pubmed: 33863342
Clin Rehabil. 2016 Jun;30(6):559-76
pubmed: 26198892
Psychol Rev. 1977 Mar;84(2):191-215
pubmed: 847061
J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):13-9
pubmed: 24828900
Health Expect. 2001 Mar;4(1):29-37
pubmed: 11286597
Clin Infect Dis. 1994 Jan;18 Suppl 1:S79-83
pubmed: 8148458
BMJ. 2006 Mar 4;332(7540):525-7
pubmed: 16513709
Iran J Public Health. 2015 Nov;44(11):1442-4
pubmed: 26744700
Lancet Neurol. 2019 Aug;18(8):736-747
pubmed: 31301748
Neurology. 1996 Apr;46(4):907-11
pubmed: 8780061
PLoS One. 2016 Jul 13;11(7):e0159129
pubmed: 27411042
Clin Rehabil. 2014 Sep;28(9):924-35
pubmed: 24691218
Disabil Rehabil. 2008;30(9):662-74
pubmed: 17852315
Psychol Health Med. 2012;17(6):636-51
pubmed: 22313192
Eur Neurol. 2014;72 Suppl 1:1-5
pubmed: 25278115
Disabil Rehabil. 2014;36(1):32-8
pubmed: 23594054
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
BMC Neurol. 2014 Jul 12;14:143
pubmed: 25016312
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Arch Phys Med Rehabil. 2013 Sep;94(9):1800-1828.e3
pubmed: 23669008
J Gerontol A Biol Sci Med Sci. 2013 Sep;68(9):1076-82
pubmed: 23401566
Pharmacoeconomics. 2008;26(10):847-60
pubmed: 18793032
Int J Stroke. 2015 Jul;10(5):697-704
pubmed: 24256085
Patient Relat Outcome Meas. 2016 Jun 15;7:73-80
pubmed: 27366108
Rehabil Res Pract. 2015;2015:123494
pubmed: 26491567
Physiother Can. 2016;68(1):37-45
pubmed: 27504046
BMJ Open. 2015 Jul 22;5(7):e007674
pubmed: 26201723
Lancet Neurol. 2015 Feb;14(2):194-207
pubmed: 25772898
J Neurol Neurosurg Psychiatry. 2001 Feb;70(2):174-9
pubmed: 11160464
Arch Phys Med Rehabil. 2012 Oct;93(10):1757-65
pubmed: 22575393
Health Educ Res. 2008 Aug;23(4):744-52
pubmed: 17962232
Physiotherapy. 2012 Dec;98(4):344-50
pubmed: 23122442
Brain. 2016 Sep;139(Pt 9):2395-405
pubmed: 27401521
Neurorehabil Neural Repair. 2009 Feb;23(2):108-16
pubmed: 18948413
Arch Phys Med Rehabil. 2016 Jan;97(1):141-51.e3
pubmed: 26281954
BMC Neurol. 2014 Dec 21;14:241
pubmed: 25528262